Next-generation HER2-targeted drugs include trastuzumab-duocaramzine (SYD-985) and trastuzumab-deruxtecan (DS-8201), which have demonstrated promising results in HER2 “low” breast cancer [30]. Here, ERBB2 is linked to breast carcinoma.